| Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. | |
| | |
MedLine Citation:
|
PMID: 9217875 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sulfonylurea derivatives are hypoglycemic drugs frequently used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). In the beta-cell sulfonylureas act by blocking ATP-sensitive potassium channels (K.ATP channels). In several organ systems, including the cardiovascular system, sulfonylurea receptors and functional K.ATP channels have been identified. In the heart their role is not clear: an endogenous cardioprotective effect has been suggested. There is no doubt that K.ATP channels are effectively blocked by sulfonylureas. In the last decade sulfonylureas have been widely used as a pharmacological tool in experimental (cardiac) research. Blockade of K.ATP channels is the proposed cellular mechanism of action for all sulfonylurea-related effects. However, other membrane currents are affected as well. In addition, myocardial metabolism is modified by sulfonylurea pretreatment. Hence, it should seriously be questioned whether these drugs are suitable in assessing involvement of cardiac K.ATP channels in, for example, ischemia-related events. The detrimental effects of sulfonylureas in experimental studies on myocardial ischemia have led to speculation whether the widespread use of these drugs in patients with NIDDM, most often suffering from accompanying ischemic heart disease, should be reconsidered. However, a review of the clinical literature reveals that the most consistent finding is a lower incidence of ventricular arrhythmias associated with the use of glibenclamide, while no excess mortality has been shown for this agent in NIDDM with ischemic heart disease. Despite some direct effects on systemic and coronary vasculature, there are, at present, no firm clinical data on the basis of which sulfonylurea derivatives should be withheld from the cardiac patient. |
| | |
Authors:
|
C E Schotborgh; A A Wilde |
Related Documents
:
|
8349385 - The anti-arrhythmic effect of d-ala 2, leu 5, arg 6-enkephalin and its possible mechanism. 22021185 - Polypyrrole-contained electrospun conductive nanofibrous membranes for cardiac tissue e... 7229655 - Arachidonate-induced experimental nerve infarction. 7888465 - Hypoxaemia in the general surgical ward--a potential risk factor? 19360865 - Assisted circulation using the tandemheart during very high-risk pci of the unprotected... 15753115 - The effect of cardiac resynchronization on morbidity and mortality in heart failure. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Cardiovascular research Volume: 34 ISSN: 0008-6363 ISO Abbreviation: Cardiovasc. Res. Publication Date: 1997 Apr |
Date Detail:
|
Created Date: 1997-08-11 Completed Date: 1997-08-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0077427 Medline TA: Cardiovasc Res Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 73-80 Citation Subset: IM |
Affiliation:
|
Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Arrhythmias, Cardiac / drug therapy, metabolism Diabetes Mellitus, Type 2 / drug therapy, metabolism* Humans Hypoglycemic Agents / adverse effects, pharmacology* Myocardial Infarction / drug therapy, metabolism Myocardial Ischemia / drug therapy, metabolism* Myocardium / metabolism* Potassium Channels / drug effects* Sulfonylurea Compounds / adverse effects, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Potassium Channels; 0/Sulfonylurea Compounds |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs.
Next Document: Volume reflex in diabetes.